Home › Compare › THNVF vs ABBV
THNVF yields 9.53% · ABBV yields 3.06%● Live data
📍 THNVF pulled ahead of the other in Year 1
Combined, THNVF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of THNVF + ABBV for your $10,000?
Thanachart Capital Public Company Limited, an investment holding company, provides various financial services in Thailand. It operates through six segments: Company, Securities Business, Life Insurance Business, Non-Life Insurance Business, Asset Management Business, and Hire Purchase and Leasing Business. The company offers commercial banking and asset management services; securities and derivatives brokerage, proprietary trading, borrowing and lending, and investment and financial advisory services, as well as operates as an underwriting and securities registrar. It also provides non-life insurance products in the areas of fire, automobile, marine and transportation, and miscellaneous; life and health insurance products to individuals, institutions, and organizations; and hire purchase and financials leasing services for passenger cars, as well as vehicles for commercial purposes, such as pick-ups, taxis, truck tractors and lorries, etc. The company was formerly known as National Finance Public Company Limited and changed its name to Thanachart Capital Public Company Limited in April 2006. Thanachart Capital Public Company Limited was incorporated in 1959 and is headquartered in Bangkok, Thailand.
Full THNVF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.